What No One Says Publicly About Finasteride and Hormones

Over the past year, a pattern has started to surface in quieter conversations. Not in clinics or product pages, but inside comments and group chats among women trying to deal with hair loss. A few people around me have tried finasteride, and while some mention that their hair seems to be improving, the conversation rarely ends there. There are often other comments that feel harder to define. Feeling slightly off. Lower mood. Not quite like themselves. Not dramatic enough to clearly label, but noticeable enough to bring up.

These are not universal experiences, and not everyone reports them. But they come up often enough to raise a different kind of question. Not just whether finasteride works, but what it actually feels like to be on it over time. Hair loss creates a sense of urgency that makes even imperfect solutions feel worth trying, but what is often left out of the public conversation is that finasteride is not just acting on hair. It is acting on hormone pathways, and that distinction is rarely explored in a way that feels real to the people taking it.

What Finasteride Actually Is

Finasteride is often talked about like a hair loss solution, but that is not what it was originally made for. It works by lowering DHT, a strong hormone signal made from testosterone.

Flip the switch below to see what finasteride actually changes inside the follicle.

The catch is obvious once you stop treating the scalp like it lives in a separate zip code. Finasteride changes how the body handles hormones. It does not just politely tap the follicle and leave everything else alone.

The Tradeoff Few People Talk About

NOVOGRO™ Enters From a Different Angle

A dermatologist I know through the industry once mentioned something off-camera that stayed with me: NOVOGRO™. Now that the research paper is out, I can finally talk about it out loud.

NOVOGRO™ is a proprietary class of precision molecules designed around follicle biology. The science traces back to a recent preprint,^[5] and to RE:YOU, an emerging brand building its serum around the technology.

It works across multiple pathways: NV-623 and NV-624 support the dermal papilla cells that act as the follicle's control center, and NV-273 supports the scalp environment around it. We walked through those two pathways and the data behind them in After Minoxidil, Everyone Wants a Better Answer. Is NOVOGRO™ the One?

NV-1065 is positioned around a more targeted, non-steroidal strategy for the same DHT-production pathway involved in finasteride and dutasteride, meaning DHT-related follicle stress can be addressed without leaning on the older framework that makes finasteride and dutasteride more complicated for many users.

The benchmark below puts NV-1065 head to head with dutasteride, the stronger and broader DHT-targeting cousin of finasteride, across a range of concentrations.

NV-1065 tracks closely with dutasteride across the range: it pulls level around 150 µM and edges past dutasteride at the top of the range. Block 5-alpha reductase that hard and you choke off the DHT that drives pattern thinning.

But the more interesting part is what it does not do.

The research group tested testosterone, DHT, dutasteride, and NV-1065 in a steroid-sensitive cell model. Think of it as a lab test designed to flag steroid-like behavior. Testosterone, DHT, and dutasteride increased cell growth under those conditions. NV-1065 did not.

The takeaway: NV-1065 is non-steroidal and non-hormonal. It does not drive the hormone-dependent cell growth that a steroid like testosterone, or a drug like dutasteride, can.